株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

スペインにおける骨粗しょう症向け医薬品の予測と市場分析

PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 267076
出版日 ページ情報 英文 123 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
スペインにおける骨粗しょう症向け医薬品の予測と市場分析 PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022
出版日: 2013年02月28日 ページ情報: 英文 123 Pages
概要

当レポートでは、スペインの骨粗しょう症市場について調査分析し、疾病の概要とガイドライン、競合情勢、主要薬剤の詳細情報、主要薬剤の売上予測、主要イベントの影響分析、市場促進要因・抑制要因などを検証して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
    • リスク因子
    • 生活の質(QOL)
  • 症状

第4章 疾病管理

  • 治療の概要
    • 診断・照会
    • 治療ガイドライン
    • 疾病管理
  • スペイン
    • 診断
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合企業評価
  • 製品プロファイル:主要ブランド

第6章 機会・アンメットニーズ

  • 概要
  • アンメットニーズ
    • 病気の認識・初期の診断
    • 患者コンプライアンス
    • 効能
    • 安全性
    • 治療コスト
    • 早期の治療介入
  • アンメットニーズ格差分析
  • 機会1:二重作用治療
  • 機会2:骨粗しょう症予防治療
  • 機会3:服薬・投与

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 市場展望

  • スペイン
    • 予測
    • 主なイベント
    • 発展因子・発展阻害因子

第9章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC1051CFR

Abstract

PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

The large dip in sales caused by these expiries is offset by pipeline product launches over the forecast period, with three of these being potential blockbuster drugs. This next generation of drugs typically consists of biologics and will be higher priced than the drugs losing patent protection in the first half of the forecast period.

Scope

  • Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Spain from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Spain Osteoporosis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Spain

TOC

1 Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 7
  • 1.2 List of Figures 9

2 Introduction 10

  • 2.1 Catalyst 10
  • 2.2 Related Reports 10

3 Disease Overview 13

  • 3.1 Etiology and Pathophysiology 13
    • 3.1.1 Etiology 13
    • 3.1.2 Pathophysiology 16
    • 3.1.3 Risk Factors 17
    • 3.1.4 Quality of Life 17
  • 3.2 Symptoms 18

4 Disease Management 19

  • 4.1 Treatment Overview 19
    • 4.1.1 Diagnosis and Referral 19
    • 4.1.2 Treatment Guidelines 20
    • 4.1.3 Disease Management 21
  • 4.2 Spain 23
    • 4.2.1 Diagnosis 23
    • 4.2.2 Clinical Practice 24

5 Competitive Assessment 25

  • 5.1 Overview 25
  • 5.2 Strategic Competitor Assessment 25
  • 5.3 Product Profiles - Major Brands 29
    • 5.3.1 Actonel (risedronate sodium) 29
    • 5.3.2 Evista (raloxifene hydrochloride) 32
    • 5.3.3 Reclast (zolendronic acid) 35
    • 5.3.4 Forteo (teriparatide) 38
    • 5.3.5 Prolia (denosumab) 42
    • 5.3.6 Protelos (strontium ranelate) 45
    • 5.3.7 Miacalcin and Fortical (calcitonin-salmon) 48
    • 5.3.8 Viviant/Conbriza (bazedoxifene) 51
    • 5.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 53
    • 5.3.10 Alendronate sodium 56
    • 5.3.11 Ibandronate 58

6 Opportunity and Unmet Need 59

  • 6.1 Overview 59
  • 6.2 Unmet Needs 59
    • 6.2.1 Disease Awareness and Early Diagnosis 59
    • 6.2.2 Patient Compliance 60
    • 6.2.3 Efficacy 61
    • 6.2.4 Safety 61
    • 6.2.5 Treatment Cost 62
    • 6.2.6 Earlier Intervention 62
  • 6.3 Unmet Needs Gap Analysis 63
  • 6.4 Opportunity 1: Dual-Action Therapies 64
  • 6.5 Opportunity 2: Osteoporosis Prevention Therapies 65
  • 6.6 Opportunity 3: Dosing and Administration 65

7 Pipeline Assessment 66

  • 7.1 Overview 66
  • 7.2 Promising Drugs in Clinical Development 67
    • 7.2.1 Aprela (bazedoxifene and conjugated estrogens) 68
    • 7.2.2 Romosozumab (AMG-785) 74
    • 7.2.3 Odanacatib 79
    • 7.2.4 BA-058 84
    • 7.2.5 PTH(1-31)NH2 88
    • 7.2.6 Ostora (recombinant salmon calcitonin) 93

8 Market Outlook 98

  • 8.1 Spain 98
    • 8.1.1 Forecast 98
    • 8.1.2 Key Events 101
    • 8.1.3 Drivers and Barriers 102

9 Appendix 103

  • 9.1 Bibliography 103
  • 9.2 Abbreviations 110
  • 9.3 Methodology 112
  • 9.4 Forecasting Methodology 112
    • 9.4.1 Diagnosed Osteoporosis Patients 113
    • 9.4.2 Percent Drug-Treated Patients 113
    • 9.4.3 Drugs Included in Each Therapeutic Class 113
    • 9.4.4 Launch and Patent Expiry Dates 114
    • 9.4.5 General Pricing Assumptions 114
    • 9.4.6 Individual Drug Assumptions 115
    • 9.4.7 Generic Erosion 119
    • 9.4.8 Pricing of Pipeline Agents 119
  • 9.5 Physicians and Specialists Included in this Study 120
    • 9.5.1 About the Authors 121
    • 9.5.2 Global Head of Healthcare 122
  • 9.6 About GlobalData 123
  • 9.7 Contact Us 123
  • 9.8 Disclaimer 123

List of Tables

1.1 List of Tables

  • Table 1: Etiology of Primary Osteoporosis 13
  • Table 2: Etiology of Secondary Osteoporosis 15
  • Table 3: Symptoms of Osteoporosis 18
  • Table 4: Diagnostic Tests for Osteoporosis 19
  • Table 5: T-Score Ranges for Determination of BMD 20
  • Table 6: Treatment Guidelines for Osteoporosis 21
  • Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 22
  • Table 8: Leading Treatments for Osteoporosis, 2012 28
  • Table 9: Product Profile - Actonel 30
  • Table 10: Actonel SWOT Analysis, 2012 31
  • Table 11: Product Profile - Evista 33
  • Table 12: Evista SWOT Analysis, 2012 34
  • Table 13: Product Profile - Reclast 36
  • Table 14: Reclast SWOT Analysis, 2012 37
  • Table 15: Product Profile - Forteo 39
  • Table 16: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 40
  • Table 17: Forteo SWOT Analysis, 2012 41
  • Table 18: Product Profile - Prolia 42
  • Table 19: Prolia SWOT Analysis, 2012 44
  • Table 20: Product Profile - Protelos 45
  • Table 21: Protelos SWOT Analysis, 2012 46
  • Table 22: Product Profile - Miacalcin and Fortical Nasal Spray 49
  • Table 23: Adverse Events with Miacalcin Nasal Spray 49
  • Table 24: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 50
  • Table 25: Product Profile - Viviant/Conbriza 52
  • Table 26: Viviant/Conbriza SWOT Analysis, 2012 53
  • Table 27: Product Profile - Recalbon/Bonoteo 54
  • Table 28: Recalbon/Bonoteo SWOT Analysis, 2012 55
  • Table 29: Overall Unmet Needs - Current Level of Attainment 59
  • Table 30: Clinical Unmet Needs - Gap Analysis, 2012 63
  • Table 31: Osteoporosis - Pipeline, 2012 67
  • Table 32: Comparison of Therapeutic Classes in Development for Osteoporosis, 2012 67
  • Table 33: Product Profile - Aprela 69
  • Table 34: Aprela SWOT Analysis, 2012 73
  • Table 35: Product Profile - Romosozumab 74
  • Table 36: Romosozumab SWOT Analysis, 2012 78
  • Table 37: Product Profile - Odanacatib 79
  • Table 38: Odanacatib SWOT Analysis, 2012 83
  • Table 39: Product Profile - BA-058 84
  • Table 40: BA-058 SWOT Analysis, 2012 87
  • Table 41: Product Profile - PTH(1-31)NH2 89
  • Table 42: PTH(1-31)NH2 SWOT Analysis, 2012 91
  • Table 43: Product Profile - Ostora 94
  • Table 44: Ostora SWOT Analysis, 2012 96
  • Table 45: Spain Sales Forecasts ($m) for Osteoporosis, 2012-2022 99
  • Table 46: Key Events Impacting Sales for Osteoporosis in the Spain, 2012-2022 101
  • Table 47: Osteoporosis Market - Drivers and Barriers in Spain, 2012-2022 102
  • Table 48: Key Launch Dates 114
  • Table 49: Key Patent Expiries 114
  • Table 50: Number of High-Prescribing Physicians Surveyed 120

List of Figures

1.2 List of Figures

  • Figure 1: Company Portfolio Gap Analysis in Osteoporosis, 2012-2022 68
  • Figure 2: Sales for Osteoporosis Drugs in Spain by Drug Class, 2012-2022 100
Back to Top